OmniAb (OABI) signied a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG, a joint venture between ArrowMark and Viking Global Investors. OmniAb will receive revenue for services performed as well as potential equity and royalties for the discovery of novel antibodies for targets defined by Mabtrx. ArrowMark Partners is a privately held, employee-owned investment management firm founded in 2007 and headquartered in Denver, Colorado. Founded in 1999, Viking Global Investors is a global investment firm with a long-term, fundamental, research-intensive approach to investing. Viking manages over $55B of capital across public and private investments.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OABI:
- OmniAb’s Earnings Call: Progress Amid Challenges
- OmniAb price target lowered to $7 from $10 at Craig-Hallum
- OmniAb Reports Q3 2025 Financial Results and Innovations
- OmniAb’s Innovative OmniUltra Technology and Strategic Operational Adjustments Drive Buy Rating
- OmniAb reports Q3 EPS (14c), consensus (14c)